Cingulate/ US17248W2044 /
2024-03-18 2:39:27 PM | Chg. -0.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.15USD | -0.86% | 42 Turnover: 48.30 |
-Bid Size: - | -Ask Size: - | 1.15 | 1.15 |
GlobeNewswire
02-13
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire
01-29
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingul...
GlobeNewswire
2023-12-06
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
GlobeNewswire
2023-12-05
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
GlobeNewswire
2023-12-01
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
GlobeNewswire
2023-11-13
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Updat...
GlobeNewswire
2023-10-31
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
GlobeNewswire
2023-09-11
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 ...
GlobeNewswire
2023-09-08
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
GlobeNewswire
2023-09-05
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial ...
GlobeNewswire
2022-03-10
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business ...